Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose clarithromycin after endoscopic sinus surgery for chronic rhinosinusitis
ACTRN12621000688886Phase 4Not yet recruiting
- Sponsor
- Professor Alkis Psaltis
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of clarithromycin in chronic rhinosinusitis (CRS) (2 arms), sponsored by Professor Alkis Psaltis. Primary endpoints: SNOT-21 questionnaire score, Visual analogue scale of discomfort and 1 more. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
clarithromycin
03
Conditions
chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on ACTRN12621000688886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000688886.